January 2019

Cytokinetics Announces Receipt of FDA Feedback Regarding Reldesemtiv in Patients with SMA

Cytokinetics, Incorporated (CYTK) today announced that it has received feedback from the U.S. Food and Drug Administration (FDA) that the Six Minute Walk Test (6MWT) is an acceptable primary efficacy endpoint for a potential registration program for reldesemtiv in patients with spinal muscular atrophy (SMA) who have maintained ambulatory function. The FDA also recommended adding

Cytokinetics Announces Receipt of FDA Feedback Regarding Reldesemtiv in Patients with SMA Read More »

Cure SMA is Thrilled to Launch Its New and Refreshed Endurance Program: Team Cure SMA

Start 2019 Strong by becoming a Team Cure SMA runner, registering a team or donating to a race today.  Team Cure SMA is an endurance program designed to connect runners and cyclists with Cure SMA. Cure SMA, is a 501(c)3 nonprofit organization dedicated to the treatment and cure of spinal muscular atrophy (SMA). SMA is a

Cure SMA is Thrilled to Launch Its New and Refreshed Endurance Program: Team Cure SMA Read More »

Be A Part of Cure SMA’s Valentine’s Day Advocacy Campaign and Support the Newborn Screening Saves Lives Reauthorization Act

With Valentine’s Day rapidly approaching, we are showing our love for the Newborn Screening Saves Lives Reauthorization Act! Take action to support this very important bill by sending a Valentine’s Day card to your Members of Congress. Valentine’s Day Advocacy Campaign Be an advocate for newborn screening! It is time to get artistically creative and

Be A Part of Cure SMA’s Valentine’s Day Advocacy Campaign and Support the Newborn Screening Saves Lives Reauthorization Act Read More »

Heather Tomko on Goal-Setting for the New Year

Heather Tomko, Ms. Wheelchair USA 2018, shares her tips for starting 2019 strong. Thank you to Heather for contributing to Cure SMA’s Start 2019 Strong initiative! I’m not traditionally a big “New Year’s Resolutions” type of person. I don’t know exactly what it is – maybe it’s partially the fact that I don’t like to

Heather Tomko on Goal-Setting for the New Year Read More »

Fall 2018 Issue of Directions Now Available

The Fall 2018 issue of Directions is now available online. Please visit our Support & Care Publications page to download this issue or past issues of Directions. Our biannual newsletter builds our community by sharing stories and experiences. Families from all over the world connect with one another through Cure SMA to organize, share photos,

Fall 2018 Issue of Directions Now Available Read More »

Congratulations to the Winners of Cure SMA’s Video Contest!

Cure SMA recently hosted a video contest to raise SMA awareness and provide the opportunity for teens and young adults (aged 12 to 21) to share their experiences. The purpose of this contest is to raise awareness about the impact that SMA has on teens and young adults, and the strategies used to help navigate

Congratulations to the Winners of Cure SMA’s Video Contest! Read More »

Community Spotlight: Rebecca Smith and Micah Biello

When Micah Biello was diagnosed with spinal muscular atrophy type 1, no one in his family knew about the disease. Now four years later, Micah’s parents, grandparents, and other family members lead a Cure SMA Walk-n-Roll team named Micah’s Milers. The family has rallied around Micah. Not only do they fundraise, but they also help

Community Spotlight: Rebecca Smith and Micah Biello Read More »

Genentech, Roche and PTC Therapeutics Provide Update on Regulatory Filing for Risdiplam

On January 7th, PTC Therapeutics, Inc. provided a corporate update, which will be detailed as part of the company’s presentation at the 37th Annual J.P. Morgan Healthcare Conference. As part of the update, progress on regulatory filing for risdiplam was outlined. The risdiplam program is a collaboration between PTC, Genentech/Roche and SMA Foundation. The following

Genentech, Roche and PTC Therapeutics Provide Update on Regulatory Filing for Risdiplam Read More »

Scroll to Top